🚀 Laurus Labs: Breakout Backed by Earnings Punch

has delivered a stellar Q1 FY26 performance, reviving investor confidence after a slow FY25. Technically strong and fundamentally revived — the stock is now on every radar! 🔍 Fundamental Snapshot – Q1 FY26 Revenue: ₹1,570 Cr → 🔼 +31% YoY EBITDA: ₹389 Cr → 🔼 +127% YoY EBITDA Margin: 📈 24.8% vs 14.3% last year Net Profit: ₹163 Cr → 🔼 +1,154% YoY EPS: ₹3.0 vs ₹0.2 last year Growth led by 🔬 CDMO segment (up 103%) and stable momentum in Generic FDF (up 12%) Management expects strong order visibility, improved profitability, and scaling in fermentation & ADC platforms 📈 Technical View 📌 Stock broke out of a consolidation zone (~₹700) with heavy volume 💡 RSI near 81 → stock is overbought in short term, but strong momentum persists Support levels: ₹800–820 zone Resistance levels: ₹860–880 zone (possible near-term hurdle) 📊 Our View: Short-Term: ✅ Momentum intact, but likely to consolidate or cool off due to overbought RSI. Use dips toward ₹800 for fresh entry. Long-Term: 🔒 Re-rating candidate! CDMO growth, expanding margins, and improved execution make it a strong structural story in specialty pharma 📝 Takeaway (Post Caption Style) Laurus Labs – Revival Mode ON 🔋 Q1 EPS up 13x, CDMO fires on all cylinders, and breakout confirmed on charts. While RSI hints at short-term cooling, the long-term picture is turning very bullish! 💰 Buy on dips for positional investors. 🔁 Wait for consolidation if entering fresh in short term